Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) announced that its executive team will participate in The Small Cap Showcase & WTR Insights on June 9, 2026, in New York City.
CEO Kirk Hunstman will present at 11:30 am ET, with a live and replay webcast available via the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – VVOS
In the Jun 8 session, VVOS gained 0.64%, reflecting a mild positive market reaction. Argus tracked a peak move of +47.4% during that session. Argus tracked a trough of -11.0% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 05 | Debt-to-equity exchange | Positive | +24.8% | Exchange of up to $4.5M senior debt to equity to aid Nasdaq compliance. |
| May 20 | Q1 2026 earnings | Neutral | -0.9% | Strong revenue and margin growth offset by higher operating expenses and net loss. |
| Apr 15 | FY 2025 results | Negative | -25.9% | Higher 2025 revenue accompanied by sharply wider losses and negative equity. |
| Apr 15 | Results scheduling | Neutral | +8.9% | Announcement of date and webcast details for full-year 2025 results call. |
| Apr 07 | Private placement | Negative | -5.3% | Private placement raising $2.25M with warrants, adding capital but implying dilution. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent stock moves tended to align with the tone of fundamental financing and results announcements, with only one notable divergence on a neutral scheduling release.
Over the last few months, VVOS has focused on strengthening its balance sheet and funding operations. A June 5, 2026 debt‑to‑equity exchange agreement of up to $4.5M with Streeterville supported Nasdaq listing efforts and coincided with a 24.84% gain. Earlier, the company reported Q1 2026 revenue of about $5.1M (up 70% YoY) but with a wider $7.8M net loss, and full‑year 2025 revenue of $17.5M alongside a deeper operating loss. A $2.25M March 31, 2026 private placement helped fund its evolving medical affiliation strategy.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today announced that members of its executive management team will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City.
Representing the Company, Kirk Hunstman, CEO, will deliver a corporate presentation at 11:30 am ET and will participate in one-on-one meetings with pre-qualified investors throughout the day.
The Small Cap Showcase & WTR Insights brings together executive management teams from approximately 20 micro and small-cap companies across a diverse range of industries. This event provides a unique forum to discover differentiated investment opportunities through company presentations, one-on-one meetings, industry insights, and networking.
For more information about The Small Cap Showcase & WTR Insights, please visit www.smallcapshowcase.com.
A live webcast of the Company's presentation will be available at: Vivos Conference Webcast
A replay of the presentation will be available following the event and may also be accessed through the Company's website under the Investor Relations section.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children.
OSA affects over 1 billion people worldwide, yet
Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, the presentations described herein, and statements of the Company’s management and third parties made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “aim,” “goal” and derivations of such words and similar expressions about the future are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual benefits of debt restructuring, potential equity raise, the Company’s new model and actual revenue and cash flow results) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to raise the required new equity timely or in sufficient amounts, which would cause the commitment debt-to-equity exchange to become null and void; (ii) the risk that Vivos may be unable benefit fully or at all from the transactions discussed herein, even if they are consummated, (iii) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (iv) the risk that some patients may not achieve the desired results from using Vivos products, (v) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (vi) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing due to, among other things, a deficiency in its stockholders’ equity; (vii) market and other conditions, and (viii) other risk factors described in Vivos’ filings with the SEC. Vivos’ filings can be obtained free of charge at https://vivos.com/investors/sec-filings/. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Vivos Investor Relations and Media Contact:
Jennifer Hauser
Investor Relations Contact
investors@vivoslife.com
